

Supplementary Table 1: Characteristics of participants across endotypes in the newly-diagnosed T2D cohorts

A. Characteristics of participants across endotypes in the PNDS cohort (n = 496)

	MIND	LYDD	LYRD	SIND	p-value
N (%)	134 (27)	117 (24)	152 (30)	93 (19)	-
Clinical parameters					
Age, years	51 (43, 61)	57 (49, 67)	52 (42, 60)	58 (48, 66)	<0.001
Women, n (%)	41 (31)	40 (34)	58 (38)	23 (25)	0.16
BMI, kg/m ²	27.7 (25.4, 31.5)	28.1 (25, 32.5)	30.3 (26.8, 33.7)	29.4 (25.8, 33.7)	0.009
Active smoking, n (%)	16 (12)	17 (16)	31 (22)	16 (18)	0.19
Immune cell profile					
Leukocyte, G/L	4.70 (4.00, 5.20)	6.20 (5.60, 6.90)	6.85 (6.10, 7.48)	8.70 (7.70, 9.20)	<0.001
Neutrophil, G/L	2.29 (1.81, 2.72)	3.94 (3.32, 4.55)	3.45 (2.89, 4.04)	5.17 (4.63, 5.77)	<0.001
Lymphocyte, G/L	1.77 (1.45, 2.09)	1.60 (1.40, 1.80)	2.52 (2.38, 2.99)	2.42 (2.00, 2.78)	<0.001
Monocyte, G/L	0.36 (0.32, 0.41)	0.47 (0.39, 0.53)	0.49 (0.43, 0.57)	0.65 (0.59, 0.76)	<0.001
Insulin secretion and insulin sensitivity					
HOMA2-B, %	65 (48, 84)	55 (44, 86)	72 (45, 99)	70 (47, 90)	0.3
HOMA2-IR	1.56 (1.12, 1.99)	1.91 (1.38, 2.64)	1.65 (1.30, 2.22)	2.08 (1.47, 2.51)	<0.001
Metabolic and biochemical profiles					
HbA1c, %	6.7 (6.2, 7.7)	7.0 (6.3, 8.7)	6.8 (6.3, 7.7)	7.0 (6.4, 8.3)	0.34
hs-CRP, mg/L	1.4 (0.6, 2.8)	2.5 (1.1, 5.1)	1.7 (1, 3.2)	3.1 (1.3, 6.2)	<0.001
Total cholesterol, g/L	1.84 (1.56, 2.04)	1.83 (1.49, 2.17)	1.85 (1.62, 2.12)	1.8 (1.47, 2.06)	0.64
LDL-cholesterol, g/L	1.14 (0.9, 1.34)	1.1 (0.84, 1.42)	1.12 (0.87, 1.36)	1.05 (0.83, 1.34)	0.8
HDL-cholesterol, g/L	0.45 (0.39, 0.55)	0.43 (0.36, 0.5)	0.43 (0.37, 0.5)	0.39 (0.34, 0.46)	<0.001
Triglycerides, g/L	0.97 (0.71, 1.27)	1.12 (0.77, 1.67)	1.16 (0.82, 1.81)	1.22 (0.92, 1.7)	<0.001
AST, UI/L	29 (23, 34)	27 (23, 33)	27 (23, 35)	27 (22, 34)	0.9
ALT, UI/L	27 (19, 41)	29 (20, 43)	30 (22, 43)	28 (21, 45)	0.56
eGFR, ml/min/1.73 m ² (CKD-EPI)	98 (83, 109)	94 (80, 103)	102 (91, 110)	95 (83, 106)	0.002
Medications usage					
Biguanide (%)	90 (67)	77 (66)	98 (64)	62 (67)	0.97
Sulfonylurea (%)	16 (12)	19 (16)	20 (13)	12 (13)	0.78
DDP4 inhibitors (%)	18 (13)	19 (16)	16 (11)	10 (11)	0.5
GLP1-RA (%)	13 (9.7)	6 (5.1)	21 (14)	12 (13)	0.11
SGLT2 inhibitors (%)	1 (0.7)	5 (4.3)	7 (4.6)	6 (6.5)	0.088
Insulin (%)	12 (9)	7 (6)	19 (13)	11 (12)	0.3

B. Characteristics of participants across endotypes in the VNDS cohort (n = 661)

	MIND	LYDD	LYRD	SIND	p-value
N (%)	195 (29)	171 (26)	178 (27)	117 (18)	-
Clinical data					
Age, years	61 (54, 66)	61 (53, 68)	59 (50, 65)	58 (50, 66)	0.08
Women, n (%)	78 (40)	57 (33)	56 (31)	30 (26)	0.06
BMI, kg/m ²	28.7 (26.1, 31.2)	29.6 (26.7, 33.8)	29.7 (26.9, 33.5)	30.2 (27.9, 35.1)	0.13
Active smoking, n (%)	12 (6)	29 (17)	35 (20)	37 (33)	< 0.001
Immune cell profile					
Leukocyte, G/L	4.90 (4.40, 5.30)	6.20 (5.80, 6.90)	6.90 (6.20, 7.30)	8.40 (7.40, 9.40)	<0.001
Neutrophil, G/L	2.50 (2.08, 2.86)	3.86 (3.41, 4.47)	3.39 (2.92, 3.77)	4.86 (4.04, 5.51)	<0.001
Lymphocyte, G/L	1.79 (1.59, 2.08)	1.79 (1.54, 1.94)	2.66 (2.44, 3.08)	2.42 (2.06, 2.98)	<0.001
Monocyte, G/L	0.37 (0.32, 0.43)	0.47 (0.41, 0.53)	0.52 (0.44, 0.59)	0.71 (0.63, 0.79)	<0.001
Insulin secretion and insulin sensitivity					
HOMA2-B, %	83.1 (61.1, 111.1)	87.9 (63.7, 115.8)	93.1 (68.2, 123.8)	92.7 (70.3, 127.4)	0.2
HOMA2-IR	2.2 (1.6, 2.8)	2.6 (1.9, 3.375)	2.6 (1.9, 3.175)	2.7 (2.075, 3.6)	<0.001
Derivative control of insulin secretion,					
{pmol/[(mmol/L)/min]}/m ² BSA	551 (131, 929)	402 (53, 945)	398 (34, 1,045)	422 (0, 1,043)	0.71
Proportional control of insulin secretion,					
[(pmol/min)/(mmol/L)]/m ² BSA	57 (31, 81)	44 (25, 76)	46 (25, 77)	44 (23, 72)	0.09
M-value, μ mol/min/m ² BSA	706 (471, 1,006)	541 (367, 794)	538 (287, 792)	521 (351, 736)	<0.001
Metabolic and biochemical profiles					
HbA1c, %	6.5 (6.0, 7.2)	6.7 (6.2, 7.3)	6.6 (6.2, 7.1)	6.6 (6.2, 7.4)	0.26
hs-CRP, mg/L	1.5 (0.9, 3.0)	2.5 (1.3, 4.5)	2.2 (1.4, 4.2)	4.1 (1.3, 6.5)	<0.001
Total cholesterol, g/L	1.85 (1.6, 2.13)	1.92 (1.65, 2.2)	1.93 (1.63, 2.18)	1.8 (1.54, 1.98)	0.015
LDL-cholesterol, g/L	1.27 (1.02, 1.5)	1.34 (1.1, 1.62)	1.29 (1.08, 1.54)	1.22 (1.04, 1.47)	0.022
HDL-cholesterol, g/L	0.46 (0.39, 0.55)	0.43 (0.36, 0.5)	0.43 (0.37, 0.52)	0.4 (0.33, 0.47)	<0.001
Triglycerides, g/L	1.12 (0.81, 1.6)	1.2 (0.93, 1.75)	1.39 (0.94, 2.04)	1.4 (0.93, 1.89)	<0.001
AST, UI/L	20 (16, 25)	20 (15, 25)	20 (16, 25)	19 (15, 26)	0.64
ALT, UI/L	28 (21, 39)	26 (21, 34)	28 (22, 39)	27 (21, 36)	0.09
Medications usage					
Biguanide (%)	29 (15)	31 (18)	20 (11)	18 (15)	0.34
Sulfonylurea (%)	8 (4)	8 (5)	5 (3)	6 (5)	0.71
DDP4 inhibitors (%)	0 (0)	0 (0)	0 (0)	0 (0)	-
GLP1-RA (%)	0 (0)	0 (0)	0 (0)	0 (0)	-
SGLT2 inhibitors (%)	0 (0)	0 (0)	0 (0)	0 (0)	-
Insulin (%)	3 (2)	1 (1)	1 (1)	3 (3)	0.4

C. Characteristics of participants across endotypes in the GDS cohort (n = 406)

	MIND	LYDD	LYRD	SIND	p-value
N (%)	86 (21)	103 (25)	152 (37)	65 (16)	-
Clinical data					
Age, years	54 (47, 60)	56 (48, 61)	53 (47, 59)	52 (47, 61)	0.572
Women, n (%)	34 (40)	33 (32)	65 (43)	16 (25)	0.051
BMI, kg/m ²	29.8 (25.9, 33.4)	31.6 (28.3, 36.5)	31.1 (26.8, 35.2)	31.3 (27.9, 36.8)	0.017
Active smoking, n (%)	8 (9)	24 (24)	42 (28)	17 (26)	0.012
Immune cell profile					
Leukocyte, G/L	5.20 (4.70)	6.70 (6.00, 7.30)	7.20 (6.50, 8.22)	8.00 (7.20, 8.70)	<0.001
Neutrophil, G/L	2.84 (2.44, 3.30)	4.25 (3.81, 4.76)	3.86 (3.30, 4.52)	4.56 (3.95, 5.34)	<0.001
Lymphocyte, G/L	1.91 (1.62, 2.14)	1.75 (1.46, 2.05)	2.71 (2.48, 3.02)	2.27 (2.07, 2.61)	<0.001
Monocyte, G/L	0.26 (0.19, 0.34)	0.38 (0.30, 0.46)	0.41 (0.31, 0.53)	0.73 (0.64, 0.83)	<0.001
Insulin secretion and insulin sensitivity					
HOMA2-B, %	81.3 (62.6, 109.4)	85.6 (67.4, 125.7)	93.3 (63.9, 118.4)	98.3, 70.6, 134.2)	0.086
HOMA2-IR	2.1 (1.4, 2.8)	2.5 (1.9, 3.3)	2.5 (1.8, 3.3)	3.0 (2.1, 3.8)	<0.001
Early phase of insulin secretion, iAUC	2.0 (0.5, 6.6)	3.8 (0.2, 7.7)	3.3 (0.1, 7.5)	2.5 (-1.2, 8.8)	0.876
Total phase of insulin secretion, iAUC	85.6 (56.7, 133.5)	98.6 (72.0, 138.7)	91.8 (54.1, 141.5)	94.7 (52.3, 176.4)	0.539
M-value, mg/(kg*min)	6.6 (4.8, 8.2)	6.3 (4.3, 8.0)	5.5 (4.3, 7.5)	4.9 (3.6, 6.4)	<0.001
Metabolic and biochemical profiles					
HbA1c, %	6.3 (5.8, 6.8)	6.2 (5.9, 6.9)	6.3 (6, 6.8)	6.3 (5.9, 6.8)	0.748
hs-CRP, mg/L	1.6 (0.9, 3.7)	2.9 (1.2, 6)	2.6 (1.4, 5.7)	3.3 (1.7, 6.2)	0.001
Total cholesterol, g/L	2.04 (1.7, 2.36)	1.93 (1.74, 2.18)	1.96 (1.78, 2.26)	1.96 (1.75, 2.18)	0.728
LDL-cholesterol, g/L	1.28 (1.04, 1.55)	1.23 (1.08, 1.48)	1.29 (1.04, 1.51)	1.32 (1.06, 1.55)	0.813
HDL-cholesterol, g/L	0.46 (0.39, 0.54)	0.45 (0.38, 0.54)	0.45 (0.39, 0.54)	0.42 (0.36, 0.51)	0.15
Triglycerides, g/L	1.19 (0.78, 1.78)	1.21 (0.97, 1.9)	1.35 (1.01, 1.9)	1.43 (0.95, 2.04)	0.067
AST, UI/L	23 (20, 29)	23 (20, 28)	22 (19, 28)	23 (19, 29)	0.801
ALT, UI/L	29 (22, 37)	29 (21, 37)	29 (20, 41)	34 (26, 48)	0.064
eGFR, ml/min/1.73m ²	90.1 (77.8, 100.0)	86.4 (75.7, 94.0)	87.8 (74.0, 95.6)	87.9 (73.7, 100.6)	0.094
Albuminuria (log10)	0.6 (0.2, 1.1)	0.8 (0.3, 1.1)	0.7 (0.3, 1.1)	1.1 (0.4, 1.3)	0.007
Medications usage					
Biguanide (%)	32 (37)	53 (51)	87 (57)	43 (66)	0.003
Sulfonylurea (%)	4 (5)	0 (0)	0 (0)	2 (3)	-
DDP4 inhibitors (%)	4 (5)	7 (7)	10 (7)	5 (8)	0.884
GLP1-RA (%)	0 (0)	1 (1)	0 (0)	0 (0)	-
SGLT2 inhibitors (%)	1 (1)	1 (1)	0 (0)	0 (0)	-
Insulin (%)	5 (6)	7 (7)	15 (10)	4 (6)	0.618

Continuous variables were reported as median (first quartile, third quartile) or mean (standard deviation) and categorical variables as frequencies (percentages). Comparisons between endotypes were performed using the Kruskal–Wallis test or Fisher's exact test where appropriate.

Supplementary Table 2: Characteristics of participants across endotypes in the longitudinal T2D cohorts

A. Characteristics of participants across endotypes in the CODIA cohort (n = 71,409)

	MIND	LYDD	LYRD	SIND	p-value
N (%)	12,099 (17)	23,257 (32)	14,932 (21)	21,121 (30)	
Clinical parameters					
Age, years	57 (46, 67)	64 (49, 74)	56 (44, 66)	63 (48, 74)	<0.001
Women, n (%)	6,293 (52)	11,543 (50)	8,511 (57)	10,010 (47)	<0.001
Active smoking, n (%)	1954 (16.2)	3799 (16.3)	2861 (19.2)	3986 (18.9)	<0.001
BMI, kg/m ²	28.1 (6.1)	28.4 (6.2)	30.1 (6.4)	29.5 (6.5)	<0.001
Immune cell profile					
Neutrophil, G/L	2.27 (0.62)	4.28 (1.01)	3.36 (0.86)	5.14 (0.99)	<0.001
Lymphocyte, G/L	1.63 (0.48)	1.44 (0.42)	2.79 (0.59)	2.12 (0.61)	<0.001
Monocyte, G/L	0.36 (0.10)	0.48 (0.11)	0.51 (0.10)	0.74 (0.16)	<0.001
Metabolic and biochemical profiles					
HbA1c, %	6.6 (2.4)	6.3 (2.1)	7.0 (2.5)	6.5 (2.1)	<0.001
hs-CRP (mg/L)	3.86 (9.07)	5.3 (13.49)	4.35 (9.05)	6.07 (13.53)	<0.001
Lipids profile (mmol/L)					
Total cholesterol	4.62 (1.14)	4.53 (1.21)	4.68 (1.16)	4.48 (1.20)	<0.001
LDL cholesterol	2.66 (0.94)	2.54 (0.96)	2.7 (0.97)	2.49 (0.98)	<0.001
HDL cholesterol	1.51 (0.63)	1.45 (0.61)	1.44 (0.71)	1.36 (0.59)	<0.001
Triglyceride	1.36 (1.63)	1.56 (1.24)	1.78 (1.75)	1.79 (1.37)	<0.001
eGFR, mL/min/1.73m ²	126 (130)	138 (155)	116 (61)	128 (121)	<0.001

B. Characteristics of participants across endotypes in the SURDIAGENE cohort (n = 920)

	MIND	LYDD	LYRD	SIND	p-value
N (%)	268 (29)	262 (28)	255 (28)	135 (15)	-
Clinical parameters					
Age, years	63 (10)	67 (10)	62 (11)	66 (10)	<0.001
Women, n (%)	122 (45)	92 (35)	128 (50)	46 (34)	<0.001
Diabetes duration, years	13.3 (9.4)	14.5 (9.5)	12.8 (10.0)	14.0 (9.1)	0.196
Active smoking, n (%)	23 (8.7)	24 (9.3)	31 (12.5)	21 (15.6)	0.126
ASCVD history, n (%)	35 (13.1)	56 (21.4)	48 (18.8)	30 (22.2)	0.046
BMI, kg/m ²	31.0 (5.8)	31.1 (5.7)	31.9 (6.0)	31.8 (6.2)	0.237
Immune cell profile					
Leukocyte, G/L	5.0 (4.5, 5.6)	6.9 (6.3, 7.5)	7.4 (6.6, 8.0)	9.0 (8.4, 10.0)	<0.001
Neutrophil, G/L	2.8 (2.3, 3.3)	4.5 (4.0, 5.2)	3.9 (3.4, 4.4)	5.8 (5.2, 6.3)	<0.001
Lymphocyte, G/L	1.7 (1.3, 2.0)	1.5 (1.2, 1.8)	2.6 (2.3, 2.9)	2.3 (1.9, 2.8)	<0.001
Monocyte, G/L	0.4 (0.3, 0.4)	0.5 (0.4, 0.6)	0.5 (0.4, 0.6)	0.8 (0.7, 0.9)	<0.001
Metabolic and biochemical profiles					
HbA1c, %	7.7 (1.5)	7.6 (1.5)	8.0 (1.7)	7.7 (1.4)	0.033
hs-CRP (mg/L)	2.2 (1.0, 3.9)	3.2 (1.2, 6.1)	2.7 (1.4, 4.6)	4.4 (2.5, 8.0)	<0.001
Lipids profile (mmol/L)					
HDL cholesterol	0.48 (0.16)	0.47 (0.16)	0.46 (0.15)	0.48 (0.17)	0.33
LDL cholesterol	1.05 (0.35)	0.97 (0.36)	1.05 (0.35)	1.03 (0.37)	0.037
Triglyceride	1.33 (0.97, 2.00)	1.23 (0.89, 1.84)	1.50 (1.04, 2.16)	1.37 (1.07, 2.01)	0.006
eGFR, mL/min/1.73m ²	78.0 (18.5)	72.4 (19.5)	80.4 (19.0)	75.4 (21.0)	<0.001
uACR, mg/mmol	2.1 (0.9, 7.3)	3.6 (1.3, 13.5)	1.8 (0.8, 7.0)	3.2 (1.1, 16.6)	<0.001
Medications usage					
Insuline, n (%)	135 (50.4)	158 (60.3)	139 (54.5)	87 (64.4)	0.023
RAS blocker, n (%)	159 (59.3)	185 (70.6)	173 (67.8)	101 (74.8)	0.006
Diuretics, n (%)	102 (38.1)	124 (47.3)	115 (45.1)	82 (60.7)	<0.001

C. Characteristics of participants across endotypes in the ANGIOSAFE cohort (n = 3307)

	MIND	LYDD	LYRD	SIND	p-value
N (%)	776 (24)	992 (30)	871 (26)	668 (20)	-
Clinical parameters					
Age, years	58 (50, 65)	65 (57, 71)	57 (50, 64)	64 (56, 71)	<0.001
Women, n (%)	321 (41)	334 (34)	433 (50)	196 (29)	<0.001
Diabetes duration, years	10 (3, 17)	12 (6, 20)	9 (3, 16)	12 (5, 19)	<0.001
Active smoking, n (%)	61 (9)	97 (11)	124 (16)	121 (20)	<0.001
ASCVD history, n (%)	75 (11)	204 (22)	102 (13)	162 (26)	<0.001
BMI, kg/m ²	27.6 (24.8, 31.1)	27.9 (25.0, 31.8)	29.3 (26.4, 32.8)	28.9 (25.5, 33.0)	<0.001
Immune cell profile					
Leukocyte, G/L	4.80 (4.20, 5.20)	6.40 (5.80, 7.10)	6.90 (6.20, 7.70)	8.40 (7.60, 9.00)	<0.001
Neutrophil, G/L	2.40 (1.94, 2.86)	4.08 (3.51, 4.73)	3.44 (2.93, 4.04)	5.09 (4.44, 5.67)	<0.001
Lymphocyte, G/L	1.76 (1.47, 2.03)	1.60 (1.36, 1.84)	2.60 (2.39, 3.01)	2.20 (1.85, 2.59)	<0.001
Monocyte, G/L	0.35 (0.29, 0.40)	0.47 (0.41, 0.54)	0.48 (0.42, 0.56)	0.68 (0.60, 0.77)	<0.001
Metabolic and biochemical profiles					
HbA1c, %	7.4 (6.6, 8.5)	7.6 (6.8, 8.6)	7.7 (6.9, 8.8)	7.7 (6.9, 8.7)	<0.001
hs-CRP (mg/L)	1.3 (0.7, 2.9)	2.1 (0.8, 4.3)	2.0 (0.9, 3.9)	2.4 (1.2, 5.0)	<0.001
Lipids profile (g/L)					
HDL cholesterol	0.46 (0.39, 0.56)	0.44 (0.38, 0.52)	0.44 (0.36, 0.52)	0.41 (0.36, 0.49)	<0.001
LDL cholesterol	1.05 (0.82, 1.31)	0.94 (0.74, 1.22)	1.05 (0.84, 1.31)	0.94 (0.72, 1.17)	<0.001
Triglyceride	0.94 (0.69, 1.40)	1.12 (0.82, 1.62)	1.26 (0.92, 1.85)	1.28 (0.94, 1.78)	<0.001
eGFR, mL/min/1.73m ²	95 (78, 104)	88 (70, 99)	97 (82, 105)	89 (70, 100)	<0.001
Medications usage					
Insuline, n (%)	229 (29)	301 (31)	256 (30)	226 (34)	0.15
Metformin, n (%)	527 (69)	695 (71)	603 (70)	449 (68)	0.58
Sulfonylurea, n (%)	229 (30)	350 (36)	310 (36)	233 (35)	0.031

Continuous variables were reported as median (first quartile, third quartile) or mean (standard deviation) and categorical variables as frequencies (percentages). Comparisons between endotypes were performed using the Kruskal–Wallis test or Fisher's exact test where appropriate.

Supplementary Table 3: Risk of cardiovascular events, all-cause mortality, and renal events across the endotypes

A. Risk of cardiovascular events, all-cause mortality, and renal events in the CODIA cohort

	MIND	LYDD	LYRD	SIND
Cardiovascular events				
N	11,817	22,464	14,421	20,367
Events, n (%)	520 (4.40)	1659 (7.39)	580 (4.02)	1521 (7.47)
Adjusted HR (95% CI)	-	1.42 (1.26 - 1.61)	1.1 (0.95 - 1.27)	1.47 (1.29 - 1.66)
Adjusted p-value	-	<0.001	0.55	<0.001
All-cause mortality				
N	11,817	22,464	14,421	20,367
Events, n (%)	426 (3.60)	1424 (6.34)	276 (1.91)	1141 (5.60)
Adjusted HR (95% CI)	-	1.24 (1.08 - 1.42)	0.56 (0.46 - 0.68)	1.18 (1.03 - 1.36)
Adjusted p-value	-	<0.001	<0.001	<0.001
Renal events				
N	11,575	21,769	14,211	19,820
Events, n (%)	295 (2.55)	820 (3.77)	228 (1.60)	631 (3.18)
Adjusted HR (95% CI)	-	1.44 (1.24 - 1.68)	0.70 (0.57 - 0.85)	1.23 (1.04 - 1.44)
Adjusted p-value	-	<0.001	<0.001	<0.001

B. Risk of cardiovascular events, all-cause mortality, and renal events in the SURDIAGENE cohort

	MIND	LYDD	LYRD	SIND
Cardiovascular events				
N	268	262	255	135
Events, n (%)	58 (22)	94 (36)	52 (20)	55 (41)
Adjusted HR (95% CI)	-	1.32 (0.94 - 1.86)	1.06 (0.72 - 1.57)	1.93 (1.32 - 2.82)
Adjusted p-value	-	<0.001	0.88	<0.001
All-cause mortality				
N	268	262	255	135
Events, n (%)	58 (22)	96 (37)	48 (19)	59 (44)
Adjusted HR (95% CI)	-	1.35 (0.97 - 1.9)	1.10 (0.74 - 1.64)	2.11 (1.45 - 3.05)
Adjusted p-value	-	0.07	0.75	<0.001
Renal events				
N	268	262	255	135
Events, n (%)	77 (30)	112 (45)	86 (36)	61 (48)
Adjusted HR (95% CI)	-	1.32 (0.98 - 1.77)	1.35 (0.99 - 1.84)	1.65 (1.17 - 2.32)
Adjusted p-value	-	0.08	0.07	0.033

C. Risk of cardiovascular events, all-cause mortality, and renal events in the ANGIOSAFE cohort

	MIND	LYDD	LYRD	SIND
Cardiovascular events				
N	631	791	726	529
Events, n (%)	61 (9.67)	156 (19.72)	98 (13.50)	137 (25.90)
Adjusted HR (95% CI)	-	1.23 (0.91 - 1.66)	1.26 (0.90 - 1.74)	1.8 (1.33 - 2.44)
Adjusted p-value	-	0.065	0.071	<0.001
All-cause mortality				
N	787	1,019	887	680
Events, n (%)	26 (3.30)	105 (10.30)	43 (4.85)	66 (9.71)
Adjusted HR (95% CI)	-	1.89 (1.22 - 2.92)	1.60 (0.98 - 2.61)	1.89 (1.19 - 2.99)
Adjusted p-value	-	0.004	0.057	0.007
Renal events				
N	110	159	140	103
Events, n (%)	30 (27.27)	48 (30.19)	23 (16.43)	36 (34.95)
Adjusted HR (95% CI)	-	1.06 (0.66 - 1.68)	0.61 (0.35 - 1.06)	1.24 (0.75 - 2.04)
Adjusted p-value	-	0.8	0.081	0.4

Continuous variables were reported as median (first quartile, third quartile) and categorical variables as frequencies (percentages). Models in CODIA were adjusted for age, gender, smoking status and SBP. Models in SURDIAGENE of CV events and mortality were adjusted for age, gender, smoking, SBP, eGFR, BMI, diabetes duration, lipid profile, albuminuria, statin, ACEI/ARB, diuretics; models in SURDIAGENE of renal events were adjusted for age, gender, baseline eGFR and ACR. Models in ANGIOSAFE were adjusted for age, gender.